- Home
- MULN vs INAB Comparison
MULN vs INAB Comparison
Compare MULN & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MULN
- INAB
- Stock Information
- Founded
- MULN 2014
- INAB 2016
- Country
- MULN United States
- INAB United States
- Employees
- MULN N/A
- INAB N/A
- Industry
- MULN Auto Manufacturing
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- MULN Consumer Discretionary
- INAB Health Care
- Exchange
- MULN Nasdaq
- INAB Nasdaq
- Market Cap
- MULN 6.5M
- INAB 14.5M
- IPO Year
- MULN N/A
- INAB 2021
- Fundamental
- Price
- MULN $0.43
- INAB $2.09
- Analyst Decision
- MULN
- INAB Strong Buy
- Analyst Count
- MULN 0
- INAB 2
- Target Price
- MULN N/A
- INAB $108.00
- AVG Volume (30 Days)
- MULN 8.6M
- INAB 385.7K
- Earning Date
- MULN 08-11-2025
- INAB 08-07-2025
- Dividend Yield
- MULN N/A
- INAB N/A
- EPS Growth
- MULN N/A
- INAB N/A
- EPS
- MULN N/A
- INAB N/A
- Revenue
- MULN $8,931,612.00
- INAB N/A
- Revenue This Year
- MULN N/A
- INAB N/A
- Revenue Next Year
- MULN N/A
- INAB N/A
- P/E Ratio
- MULN N/A
- INAB N/A
- Revenue Growth
- MULN 2136.62
- INAB N/A
- 52 Week Low
- MULN $0.42
- INAB $2.06
- 52 Week High
- MULN $150,000,000.00
- INAB $27.60
- Technical
- Relative Strength Index (RSI)
- MULN 18.77
- INAB 27.49
- Support Level
- MULN $1.62
- INAB $2.06
- Resistance Level
- MULN $1.64
- INAB $2.31
- Average True Range (ATR)
- MULN 0.57
- INAB 0.31
- MACD
- MULN 132.42
- INAB -0.00
- Stochastic Oscillator
- MULN 0.31
- INAB 4.74
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and building energy solutions. Its portfolio of vehicles is predominantly comprised of commercial trucks and other electric vehicles and includes; Mullen Class 1 Cargo Van, Mullen Three, Bollinger B4 Chassis Cab, and Mullen I-GO. The company's operating segments are Bollinger which derives maximum revenue, and Mullen Commercial.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.